SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


       Date of Report (date of earliest event reported): November 1, 2002


                          L.A.M. PHARMACEUTICAL, CORP.
                      ------ -----------------------------
             (Exact name of Registrant as specified in its charter)


     Delaware                         0-30641                  52-2278236
--------------------------------------------------------------------------------
(State or other jurisdiction   (Commission File No.)         (IRS Employer
of incorporation)                                           Identification No.)



                   800 Sheppard Avenue West, Commercial Unit 1,
                                                              -
                        Toronto, Ontario, Canada M3H 6B4
          (Address of principal executive offices, including Zip Code)


        Registrant's telephone number, including area code: (877) 526-7717
                                                            --------------



                                       N/A
                 ----------------------------------------- ----
          (Former name or former address if changed since last report)




<PAGE>



Item 5.  Other Events and Regulation FD Disclosure

Convertible Notes and Series F Warrants

      On November 1, 2002, L.A.M. sold convertible notes, plus Series A, B, C
and D warrants, to a group of private investors for $500,000. The notes do not
bear interest, are unsecured and are payable on November 1, 2005.

      At the holder's option the notes are convertible into shares of L.A.M.'s
common stock equal in number to the amount determined by dividing each $1,000 of
note principal to be converted by the Conversion Price. The initial Conversion
Price is $0.29.

      If L.A.M. sells any additional shares of common stock, or any securities
convertible into common stock at a price below the then applicable Conversion
Price, the Conversion Price will be lowered to the price at which the shares
were sold or the lowest price at which the securities are convertible, as the
case may be.

     L.A.M. has agreed to file a registration  statement with the Securities and
Exchange  Commission in order that the shares of common stock  issuable upon the
conversion  of the notes or the  exercise of the  warrants  may be resold in the
public market.

      Until 180 days after the effective date of the registration statement
which L.A.M. has agreed to file the note holders will have a first right of
refusal to participate in any subsequent financings involving L.A.M.

      Upon the occurrence of any of the following events L.A.M. is required to
redeem the notes at a price equal to 120% of then outstanding principal balance
of the notes:

          -    the  suspension  from  listing or the failure of L.A.M.'s  common
               stock to be listed on the OTC Bulletin Board for a period of five
               consecutive trading days; or

          -    the registration statement which L.A.M. has agreed to file is not
               effective by March 31, 2003

          -    the  effectiveness of the  registration  statement lapses for any
               reason or the  registration  statement is unavailable to the note
               holders and the lapse or unavailability continues for a period of
               fifteen consecutive  trading days, or 25 non-consecutive  trading
               days during any twelve  month  period,  provided the cause of the
               lapse or  unavailability  is not due to factors  primarily within
               the control of the note holders.

          -    any representation or warranty made by L.A.M. to the note holders
               proves to be materially inaccurate or L.A.M. fails to perform any
               material  covenant or  condition in its  agreement  with the note
               holders.


<PAGE>

          -    a purchase,  tender or exchange  offer accepted by the holders of
               more than 33% of L.A.M.'s outstanding shares of common stock.

          -    L.A.M.  files for protection from its creditors under the federal
               bankruptcy code.

      The Series A warrants allow the holders to purchase 426,136 shares of
L.A.M.'s common stock at a price of $0.35 per share at any time prior to
November 1, 2007.

      If L.A.M. sells any additional shares of common stock, or any securities
convertible into common stock at a price below the then applicable warrant
exercise price, the exercise price of the Series A warrants will be lowered to
the price at which the shares were sold or the lowest price at which the
securities are convertible, as the case may be.

      The Series B warrants allow the holders to purchase 937,500 shares of
L.A.M.'s common stock at a price of $0.80 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten consecutive
days that the closing bid price of L.A.M.'s common stock has exceeded $1.20,
L.A.M. has the right, upon 15 days advance written notice to the holders of the
Series B warrants, to force the holders to exercise the unexercised portion of
the Series B warrants.

      The Series C warrants allow the holders to purchase 625,000 shares of
L.A.M.'s common stock at a price of $1.20 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten consecutive
days that the closing bid price of L.A.M.'s common stock has exceeded $2.00,
L.A.M. has the right, upon 15 days advance written notice to the holders of the
Series C warrants, to force the holders to exercise the unexercised portion of
the Series C warrants.

      The Series D warrants allow the holders to purchase 468,750 shares of
L.A.M.'s common stock at a price of $1.60 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten consecutive
days that the closing bid price of L.A.M.'s common stock has exceeded $2.50,
L.A.M. has the right, upon 15 days advance written notice to the holders of the
Series D warrants, to force the holders to exercise the unexercised portion of
the Series D warrants.

      L.A.M.'s right to force the warrant holders to exercise the Series, B, C
and D warrants is subject to a number of conditions, including the following:

          -    there is in effect a registration statement which the holders may
               use  to  sell  the  shares  issuable  upon  the  exercise  of the
               warrants.

          -    L.A.M.'s  common  stock is listed for trading on the OTC Bulletin
               Board

      The exercise price of the Series B, C and D warrants is not subject to
adjustment except in the case of stock splits, consolidations and similar
transactions.

<PAGE>


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  November 1, 2002

                                 L.A.M. PHARMACEUTICAL,CORP.



                                 By:  /s/ Joseph Slechta
                                    -------------------------------------
                                      Joseph Slechta, President
[{"type": "8-K", "sequence": "1", "filename": "form8knov02.txt", "secsgml_size_bytes": 7591}]
{"company-data": {"conformed-name": "LAM PHARMACEUTICAL CORP", "cik": "0001071272", "assigned-sic": "2834", "irs-number": "522278236", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-30641", "film-number": "02807713"}, "business-address": {"street1": "800 SHEPPARD AVENUE WEST", "city": "TORONTO", "state": "A6", "zip": "00000", "phone": "4166333004"}, "mail-address": {"street1": "800 SHEPPARD AVENUE WEST", "city": "TORONTO", "state": "A6", "zip": "00000"}}
SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): November 1, 2002

                          L.A.M. PHARMACEUTICAL, CORP.
                      ------ -----------------------------
             (Exact name of Registrant as specified in its charter)

     Delaware                         0-30641                  52-2278236
--------------------------------------------------------------------------------
(State or other jurisdiction   (Commission File No.)         (IRS Employer
of incorporation)                                           Identification No.)

                   800 Sheppard Avenue West, Commercial Unit 1,
                                                              -
                        Toronto, Ontario, Canada M3H 6B4
          (Address of principal executive offices, including Zip Code)

        Registrant's telephone number, including area code: (877) 526-7717
                                                            --------------

                                       N/A
                 ----------------------------------------- ----
          (Former name or former address if changed since last report)
Item 5.  Other Events and Regulation FD Disclosure

Convertible Notes and Series F Warrants

      On November 1, 2002, L.A.M. sold convertible notes, plus Series A, B, C
and D warrants, to a group of private investors for $500,000. The notes do not
bear interest, are unsecured and are payable on November 1, 2005.

      At the holder's option the notes are convertible into shares of L.A.M.'s
common stock equal in number to the amount determined by dividing each $1,000 of
note principal to be converted by the Conversion Price. The initial Conversion
Price is $0.29.

      If L.A.M. sells any additional shares of common stock, or any securities
convertible into common stock at a price below the then applicable Conversion
Price, the Conversion Price will be lowered to the price at which the shares
were sold or the lowest price at which the securities are convertible, as the
case may be.

     L.A.M. has agreed to file a registration  statement with the Securities and
Exchange  Commission in order that the shares of common stock  issuable upon the
conversion  of the notes or the  exercise of the  warrants  may be resold in the
public market.

      Until 180 days after the effective date of the registration statement
which L.A.M. has agreed to file the note holders will have a first right of
refusal to participate in any subsequent financings involving L.A.M.

      Upon the occurrence of any of the following events L.A.M. is required to
redeem the notes at a price equal to 120% of then outstanding principal balance
of the notes:

          -    the  suspension  from  listing or the failure of L.A.M.'s  common
               stock to be listed on the OTC Bulletin Board for a period of five
               consecutive trading days; or

          -    the registration statement which L.A.M. has agreed to file is not
               effective by March 31, 2003

          -    the  effectiveness of the  registration  statement lapses for any
               reason or the  registration  statement is unavailable to the note
               holders and the lapse or unavailability continues for a period of
               fifteen consecutive  trading days, or 25 non-consecutive  trading
               days during any twelve  month  period,  provided the cause of the
               lapse or  unavailability  is not due to factors  primarily within
               the control of the note holders.

          -    any representation or warranty made by L.A.M. to the note holders
               proves to be materially inaccurate or L.A.M. fails to perform any
               material  covenant or  condition in its  agreement  with the note
               holders.
-    a purchase,  tender or exchange  offer accepted by the holders of
               more than 33% of L.A.M.'s outstanding shares of common stock.

          -    L.A.M.  files for protection from its creditors under the federal
               bankruptcy code.

      The Series A warrants allow the holders to purchase 426,136 shares of
L.A.M.'s common stock at a price of $0.35 per share at any time prior to
November 1, 2007.

      If L.A.M. sells any additional shares of common stock, or any securities
convertible into common stock at a price below the then applicable warrant
exercise price, the exercise price of the Series A warrants will be lowered to
the price at which the shares were sold or the lowest price at which the
securities are convertible, as the case may be.

      The Series B warrants allow the holders to purchase 937,500 shares of
L.A.M.'s common stock at a price of $0.80 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten consecutive
days that the closing bid price of L.A.M.'s common stock has exceeded $1.20,
L.A.M. has the right, upon 15 days advance written notice to the holders of the
Series B warrants, to force the holders to exercise the unexercised portion of
the Series B warrants.

      The Series C warrants allow the holders to purchase 625,000 shares of
L.A.M.'s common stock at a price of $1.20 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten consecutive
days that the closing bid price of L.A.M.'s common stock has exceeded $2.00,
L.A.M. has the right, upon 15 days advance written notice to the holders of the
Series C warrants, to force the holders to exercise the unexercised portion of
the Series C warrants.

      The Series D warrants allow the holders to purchase 468,750 shares of
L.A.M.'s common stock at a price of $1.60 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten consecutive
days that the closing bid price of L.A.M.'s common stock has exceeded $2.50,
L.A.M. has the right, upon 15 days advance written notice to the holders of the
Series D warrants, to force the holders to exercise the unexercised portion of
the Series D warrants.

      L.A.M.'s right to force the warrant holders to exercise the Series, B, C
and D warrants is subject to a number of conditions, including the following:

          -    there is in effect a registration statement which the holders may
               use  to  sell  the  shares  issuable  upon  the  exercise  of the
               warrants.

          -    L.A.M.'s  common  stock is listed for trading on the OTC Bulletin
               Board

      The exercise price of the Series B, C and D warrants is not subject to
adjustment except in the case of stock splits, consolidations and similar
transactions.
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  November 1, 2002

                                 L.A.M. PHARMACEUTICAL,CORP.

                                 By:  /s/ Joseph Slechta
                                    -------------------------------------
                                      Joseph Slechta, President